The COVID-19 Vaccine Safety Research Center: a cornerstone for strengthening safety evidence for COVID-19 vaccination in the Republic of Korea
10.24171/j.phrp.2023.0343
- Author:
Na-Young JEONG
1
;
Hyesook PARK
;
Sanghoon OH
;
Seung Eun JUNG
;
Dong-Hyun KIM
;
Hyoung-Shik SHIN
;
Hee Chul HAN
;
Jong-Koo LEE
;
Jun Hee WOO
;
Jaehun JUNG
;
Joongyub LEE
;
Ju-Young SHIN
;
Sun-Young JUNG
;
Byung-Joo PARK
;
Nam-Kyong CHOI
Author Information
1. COVID-19 Vaccine Safety Research Center, Seoul, Republic of Korea
- Publication Type:Special Article
- From:
Osong Public Health and Research Perspectives
2024;15(2):97-106
- CountryRepublic of Korea
- Language:EN
-
Abstract:
The COVID-19 Vaccine Safety Research Committee (CoVaSC) was established in November 2021 to address the growing need for independent, in-depth scientific evidence on adverse events (AEs) following coronavirus disease 2019 (COVID-19) vaccination. This initiative was requested by the Korea Disease Control and Prevention Agency and led by the National Academy of Medicine of Korea. In September 2022, the COVID-19 Vaccine Safety Research Center was established, strengthening CoVaSC’s initiatives. The center has conducted various studies on the safety of COVID-19 vaccines. During CoVaSC’s second research year, from September 29, 2022 to July 19, 2023, the center was restructured into 4 departments: Epidemiological Research, Clinical Research, Communication & Education, and International Cooperation & Policy Research. Its main activities include (1) managing CoVaSC and the COVID-19 Vaccine Safety Research Center, (2) surveying domestic and international trends in AE causality investigation, (3) assessing AEs following COVID-19 vaccination, (4) fostering international collaboration and policy research, and (5) organizing regular fora and training sessions for the public and clinicians. Causality assessments have been conducted for 27 diseases, and independent research has been conducted after organizing ad hoc committees comprising both epidemiologists and clinical experts on each AE of interest. The research process included protocol development, data analysis, interpretation of results, and causality assessment. These research outcomes have been shared transparently with the public and healthcare experts through various fora. The COVID-19 Vaccine Safety Research Center plans to continue strengthening and expanding its research activities to provide reliable, high-quality safety information to the public.
